Primary Squamous Cell Carcinoma of the Breast

Sj, Gauden

doi:10.1111/j.1440-1673.1992.tb03162.x

Cited by 12 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6 Several reports have attributed SqCC with a more aggressive clinical course than IDC. 21 The rate of axillary lymph node metastases in primary SqCC is 22% (Table 1); we found no data to support the claim of higher rates by Weigel et al 1 By contrast, in IDC of the breast, rates as high as 40% to 60% have been reported at presentation. Additionally, lymphatic spread is recognized as the major pathway for dissemination of the disease: hence, the importance of axillary node dissection as a staging and therapeutic procedure.…”

Section: Natural Historymentioning

confidence: 62%

Primary Squamous Cell Carcinoma (SqCC) of the Breast

Menes¹,

Schachter²,

Morgenstern³

et al. 2003

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Primary squamous cell carcinoma (SqCC) of the breast is a rare tumor that presents a unique biologic behavior. Thus, it challenges the justification for routine axillary dissection and adjuvant therapy. A MEDLINE search of all reported cases of primary SqCC of the breast was performed. Data on lymph node status, estrogen receptor (ER) and progesterone receptor (PR) status, and surgical and adjuvant treatment modalities were collected. We add three cases from our own experience. SqCC has several unique biologic characteristics; it is associated with a lower rate of lymph node metastasis at presentation (22% vs. 40-60% for infiltrating ductal carcinoma [IDC]) and a significant rate of distant metastasis without lymph node involvement. ER and PR receptor levels are usually very low. Because lymph node involvement plays a lesser prognostic and therapeutic role in this disease, we propose a more selective approach (i.e., sentinel node biopsy). The issue of adjuvant treatment remains unresolved, owing to lack of data. Surgical and medical treatment of SqCC of the breast should be tailored to fit its distinct biologic characteristics. The 5-fluorouracil-doxorubicin-cisplatin combination may be warranted in lieu of the combinations used for IDC.

show abstract

Section: Natural Historymentioning

confidence: 62%

Primary Squamous Cell Carcinoma (SqCC) of the Breast

Menes¹,

Schachter²,

Morgenstern³

et al. 2003

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Rosen and Ernsberger (1) reported 5‐year survival rates in their series of 40 patients with low‐grade adenosquamous carcinoma to be 68%, 64%, and 48% for stages I, II, and III, respectively, with overall 5‐year survival being 55%. The poor prognosis reported by others (18,19) may be a reflection of the advanced size of these tumors. Eggers and Chesney (5) and Eusebi et al (20) suggest that squamous cell carcinomas have an outcome similar to that of adenocarcinomas of a similar stage.…”

Section: Pathologic Molecular and Clinical Features Of The Six Mbc mentioning

confidence: 86%

Metaplastic Breast Carcinoma with Squamous Differentiation: Molecular and Clinical Analysis of Six Cases

et al. 2005

View full text Add to dashboard Cite

“…As reported in the literature, PSCC of the breast is an exceedingly rare malignancy. Although it was firstly reported more than 100 years ago [ 11 ], most published studies were care reports or small retrospective cohorts from a single institution [ 2 , 5 – 8 , 12 , 13 ]. Therefore, the clinical characteristics and outcomes of PSCC of the breast are limited, although most researchers who achieved a relative consistent observation across many studies indicated that PSCC has aggressive histological features at presentation and has poor outcomes [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

Lumpectomy Combined with Adjuvant Radiotherapy Could Be a Treatment Option for Primary Squamous Cell Carcinoma of the Breast

Cao

Che

et al. 2021

Journal of Oncology

View full text Add to dashboard Cite

Background. To investigate the outcomes of primary squamous cell carcinoma (PSCC) of the breast undergoing radical surgery with or without adjuvant radiotherapy (RT). Materials and Methods. A population cohort with histologically diagnosed PSCC of the breast was identified from the SEER database. The Kaplan–Meier method and Cox-regression proportional hazards model was used to assess the impact of surgical types with or without adjuvant RT on the cause-specific survival (CSS) and overall survival (OS). A retrospective analysis of PSCC between Jan 2010 and Dec 2018 from our institute was performed. Results. A total of 515 patients with PSCC of the breast were included, 254 patients treated with mastectomy (MAST) alone, 78 with MAST + RT, 87 with lumpectomy (LUMP) alone, and 96 with LUMP + RT. The median follow-up time was 118 months (range: 0–379 months). In the multivariate Cox analyses, LUMP + adjuvant RT was an independent prognostic factor for CSS (p = 0.028) and OS (p = 0.048). Patients treated with LUMP + RT had better survival rates than patients who underwent lumpectomy (CSS, p = 0.034; OS, p = 0.0004), MAST alone (CSS, p = 0.0001; OS, p < 0.0001), and MAST + RT (CSS, p = 0.0001; OS, p = 0.0078), while postmastectomy RT did not significantly improve OS (p = 0.062) and CSS (p = 0.67) when compared to MAST alone. In addition, a total of 28 patients with PSCC of the breast were identified from our institute. All of these patients presented with estrogen receptor-negative type, and three of them had HER-2-positive PSCC; the median tumor size was 3 cm (range: 0.5–15 cm). Eight patients were treated with LUMP + adjuvant RT, thirteen with MAST, and seven with MAST + RT. Until the last follow-up of Sep 2021, 26 patients with PSCC were still alive and free of breast cancer, excepting that one patient treated with MAST and one patient with MAST + RT died from breast cancer. Conclusion. PSCC of the breast after radical surgery has a poor prognosis. Adjuvant RT after LUMP significantly improves survival of patients with PSCC of the breast. Further studies are still needed to investigate the role of adjuvant RT in PSCC of the breast after mastectomy.

show abstract

Primary Squamous Cell Carcinoma of the Breast

Cited by 12 publications

References 10 publications

Primary Squamous Cell Carcinoma (SqCC) of the Breast

Primary Squamous Cell Carcinoma (SqCC) of the Breast

Metaplastic Breast Carcinoma with Squamous Differentiation: Molecular and Clinical Analysis of Six Cases

Lumpectomy Combined with Adjuvant Radiotherapy Could Be a Treatment Option for Primary Squamous Cell Carcinoma of the Breast

Contact Info

Product

Resources

About